Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday. David Risinger has ...

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

Dermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches the market, and it has just cut a deal to defray those costs.

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

- VTAMA® (tapinarof) cream, 1% demonstrated early, significant, and meaningful achievement of both no-to-minimal itch (mean weekly PP-NRS≤1) and sleep improvement in ADORING 1 and ADORING 2.

- The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. - Most patients, 81.6% (594/728 ...

Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant’s batoclimab in Phase 3 trials and namilumab in a Phase 2 trial ...